Natasha Walzer1, Laura M Kulik. 1. Feinberg School of Medicine, Division of Hepatology, Northwestern University, Chicago, Illinois, USA.
Abstract
PURPOSE OF REVIEW: This review primarily focuses on new developments in the field of hepatocellular carcinoma. RECENT FINDINGS: Potential preventive strategies in the development of hepatocellular carcinoma are being recognized. Novel molecular markers identified may aid in the diagnosis of early hepatocellular carcinoma in patients with chronic hepatitis C virus. Prognostic information gained by preoperative tumor biopsy is being investigated. Treatment of early hepatocellular carcinoma with resection versus primary or salvage transplantation continues to be debated. Expansion of selection criteria beyond the Milan criteria appears feasible. The role of living donor liver transplantation in hepatocellular carcinoma will require further study to determine the risk of recurrence. Improvements in chemoembolization with drug eluting beads appear promising. SUMMARY: Further insight into the pathogenesis of hepatocellular carcinoma will result in the continued evolution of our approach and management of the disease. Tailored therapies based on tumor biology are needed to improve treatment response and ultimately patient survival.
PURPOSE OF REVIEW: This review primarily focuses on new developments in the field of hepatocellular carcinoma. RECENT FINDINGS: Potential preventive strategies in the development of hepatocellular carcinoma are being recognized. Novel molecular markers identified may aid in the diagnosis of early hepatocellular carcinoma in patients with chronic hepatitis C virus. Prognostic information gained by preoperative tumor biopsy is being investigated. Treatment of early hepatocellular carcinoma with resection versus primary or salvage transplantation continues to be debated. Expansion of selection criteria beyond the Milan criteria appears feasible. The role of living donor liver transplantation in hepatocellular carcinoma will require further study to determine the risk of recurrence. Improvements in chemoembolization with drug eluting beads appear promising. SUMMARY: Further insight into the pathogenesis of hepatocellular carcinoma will result in the continued evolution of our approach and management of the disease. Tailored therapies based on tumor biology are needed to improve treatment response and ultimately patient survival.
Authors: Iván Lyra-González; Laura Esther Flores-Fong; Ignacio González-García; David Medina-Preciado; Juan Armendáriz-Borunda Journal: Hepatol Int Date: 2012-04-25 Impact factor: 6.047